Simplified PESI (Pulmonary Embolism Severity Index: sPESI)
Estimates the 30-day mortality risk following acute pulmonary embolism.
제공자안내
The Simplified PESI (sPESI) is used in the setting of acute pulmonary embolism (PE) to estimate a patient's 30-day mortality risk. This value helps determine if the patient is a candidate for outpatient PE management.
Patients with a LOW mortality risk (ePESI of 0) may be candidate for OUTPATIENT PE management (30-day mortality risk of 1.1%).
Patients with HIGH mortality risk (ePESI of 1 or greater) are recommended for INPATIENT PE management (30-day mortality risk of 8.9% or greater).
The sPESI was designed to remove the complexity associated with the elements of the Pulmonary Embolism Severity Index (PESI) Risk Calculator in risk stratifying patients with Pulmonary Embolism (PE).
The sPESI has been:
- Shown to be equally accurate as the PESI in predicting the 30-day mortality after acute PE.
- Externally validated, demonstrating good discrimination, calibration, and generalizability of its predictive accuracy.
- Found to be predictive of high-risk adverse outcomes with a sensitivity of 94% and specificity of 40%.
Validation Studies: Jimenez 2010, Zhou 2012, Lankeit 2011.
It is important to note that:
- The sPESI is only meant for risk stratification of PE following diagnosis, and can not be used to risk stratify patients without PE.
- Additional pathology which could lead to morbidity or mortality should not be overlooked in the setting of low risk sPESI scores.
- The patient's social situation should be taken into account alongside the sPESI score, when determining the appropriateness of outpatient PE management.
The sPESI is meant to aid in clinical decision making, not as a replacement. Clinical judgement should always take precedence.
In the setting of renal failure or severe complicating comorbidities, clinical judgement should be used over the ePESI, as these patients were excluded in the validation studies.
Criteria
If any of the following criteria is/are present, the patient is considered to have a HIGH 30-day mortality risk (8.9% or greater).
| Age (years) | ≤ 80 (0 points) | > 80 (1 point) |
| Heart Rate (bpm) | < 110 (0 points) | ≥ 110 (1 point) |
| Oxygen Saturation | ≥ 90% (0 points) | < 90% (1 point) |
| Systolic Blood Pressure | ≥ 100(0 points) | < 100 (1 point) |
| History of Cancer | No (0 points) | Yes (1 point) |
| History of Chronic Cardiopulmonary Disease | No (0 points) | Yes (1 point) |
Results
Low-Mortality Risk: sPESI = 0
If no criteria are positive, the 30-day risk of mortality is 1.1%.
Patient may be a candidate for Outpatient PE management.
High Mortality Risk: sPESI ≥ 1
If any criteria are positive, the 30-day risk of mortality is 8.9% or higher.
Patient is a candidate for Inpatient PE management.
모든 질문 및 가능한 결과
Guidance제목이 표시되지 않음
Age
Select one option:
- ≤ 80 years
- > 80 years
History of Cancer
Select one option:
- No
- Yes
History of chronic cardiopulmonary disease
Select one option:
- No
- Yes
Heart Rate
Select one option:
- < 110 bpm
- ≥ 110 bpm
Systolic Blood Pressure
Select one option:
- ≥ 100 mmHg
- < 100 mmHg
Oxygen Saturation
Select one option:
- ≥ 90%
- < 90%
가능한 결과
인용
Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010 Aug 9;170(15):1383-9. doi: 10.1001/archinternmed.2010.199. PMID: 20696966.
문헌
Derivation and validation of a prognostic model for pulmonary embolism
https://pubmed.ncbi.nlm.nih.gov/16020800/Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism
https://pubmed.ncbi.nlm.nih.gov/20696966/The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: a meta-analysis
https://pubmed.ncbi.nlm.nih.gov/23210843/Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study
https://pubmed.ncbi.nlm.nih.gov/22082681/
- 작성자
Dr. David Jiménez, MDAssociate Professor of Medicine at the University of Alcalá, Madrid, Spain, and Chief of the Venous Thromboembolism Programme at the Ramón y Cajal Hospital in Madrid, where he serves as Chief of the Respiratory Department.
- 제공
OSU Center for Health Sciences
- 기여자
Kelly Rudd, PharmD, BCPS, CACP, FCCPClinical Associate Professor of Medicine, Oklahoma State University Center for Health SciencesOSU Center for Health Sciences
- 검토자
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation